Oncology Horizons: Precision Cellular Reprograming with RNA Therapeutics

SeekR drugs are self-delivering RNA oligonucleotide compounds which can easily be synthesized using solid phase chemistry. The aptamer-based binding to specific cell surface receptors, followed by efficient receptor mediated endocytosis, enables precise and directed delivery to any receptor defined cell sub type. Oligon RNA Therapeutics is focused on bringing RNAi multitargeted immunotherapies to the clinic, including the IO SeekR Program which selectively reprograms CTLA4+ T-cells to overcome cancer immunotherapy resistance, and the RA SeekR Program focused on transforming outcomes for patients with autoimmune and inflammatory diseases.